Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine

Acta Academiae Medicinae Sinicae

Volumn 29, Issue 5, 2007, Pages 584-591

  Wang, Qing Yong ^a   Xu, Yu Fei ^a   Fan, Dong Sheng ^a   Peng, Qing Lin ^a   Zhang, Ting ^a   Xu, Xue Mei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

CD40 ligand; Cervical cancer; DNA vaccine; Human papillomavirus

Indexed keywords

CD40 LIGAND; DNA VACCINE; PROTEIN E7; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; GENE SYNTHESIS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; VIRUS INFECTION;

ANIMALS; ANTIGENS, CD40; CANCER VACCINES; CELL LINE, TUMOR; GENE FUSION; HUMAN PAPILLOMAVIRUS 16; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS VACCINES; VACCINES, DNA;

EID: 36249028755     PISSN: 1000503X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wu RF, Dai M, Qiao YL, et al. Human papillomavirus infection in women in Shenzhen city, people's Republic of China, a population typical of recent Chinese urbanization [J]. Int J Cancer, 2007, 121 (6):1306-1311.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer [J]. N Engl J Med, 2003, 348(6):518-527.
3. Kamangar F, Qiao YL, Schiller JT, et al. Human papillomavirus serology and the risk of esophageal and gastric cancers: results from a cohort in a high-risk region in China [J]. Int J Cancer, 2006, 119(3):579-584.
4. Wu Y, Chen Y, Li L, et al. Associations of high-risk HPV types and viral load with cervical cancer in China [J]. J Clin Virol, 2006, 35(3):264-269.
5. Gomez-Gutierrez JG, Elpek KG, Montes de Oca-Luna R, et al. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumor in mice [J]. Cancer Immunol Immunother, 2007, 56(7):997-1007.
6. Chinese source.
7. Kang TH, Lee JH, Bae HC, et al. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments [J]. Immunol Lett, 2006, 106(2):126-134.
8. Motoyama S, Ladines-Llave CA, Luis Villanueva S, et al. The role of human papillomavirus in the molecular biology of cervical carcinogenesis [J]. Kobe J Med Sci, 2004, 50(1-2):9-19.
9. Chinese source.
10. Shi W, Bu P, Liu J, et al. Human papillomavirus type 16 E7 DNA vaccine: mutation in the open reading frame of E7 enhances specific cytotoxic T-lymphocyte induction and anti-tumor activity [J]. J Virol, 1999, 73(9):7877-7881.
11. Smahel M, Sima P, Ludvikova V, et al. Modified HPV16 E7 genes as DNA vaccine against E7-containing oncogenic cells [J]. Virology, 2001, 281(2):231-238.
12. Firzlaff JM, Galloway DA, Eisenman RN, et al. The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II [J]. New Biol, 1989, 1(1):44-53.
13. Chinese source.
14. Ohlschlager P, Pes M, Osen W, et al. An improved rearranged human papillomavirus type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response [J]. Vaccine, 2006, 24(15):2880-2893.
15. Brinkman JA, Xu X, Kast WM. The efficacy of a DNA vaccine containing inserted and replicated regions of the E7 gene for treatment of HPV-16 induced tumors [J]. Vaccine, 2007, 25(17):3437-3444.
16. Osen W, Peiler T, Ohlschlager P, et al. A DNA vaccine based on a shuffled E7 oncogene of the human papillomavirus type 16 (HPV 16) induces E7-specific cytotoxic T cells but lacks transforming activity [J]. Vaccine, 2001, 19 (30):4276-4286.
17. Fraser IH, Thomas R, Zhou J, et al. Potential strategies utilised by papillomavirus to evade host immunity [J]. Immunol Rev, 1999, 168(1):131-142.
18. Velders MP, Weijzen S, Eiben GL, et al. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine [J]. J Immunol, 2001, 166(9):5366-5373.
19. Steinberg T, Ohlschlager P, Sehr P, et al. Modification of HPV16 E7 genes: correlation between the level of protein expression and CTL response after immunization of C57BL/6 mice [J]. Vaccine, 2005, 23:1149-1157.
20. Liu WJ, Gao F, Zhao KN, et al. Codon modified human papillomavirus type 16 E7 DNA vaccine enhances cytotoxic T-lymphocyte induction and anti-tumour activity [J]. Virology, 2002, 301(1):43-52.
21. Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies [J]. J Virol, 2003, 77(8): 4928-4937.
22. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer [J]. Cancer Gene Ther, 2003, 10(1):1-13.
23. Van Kooten C, Banchereau J. CD40-CD40 ligand [J]. J Leukoc Biol, 2000, 67(1):2-17.
24. Peng X, Remacle JE, Kasran A, et al. IL-12 up-regulates CD40 ligand (CD154) expression on human T cells [J]. J Immunol, 1998, 160(3):1166-1172.
25. Wurtzen PA, Nissen MH, Claesson MH. Maturation of dendritic cells by recombinant human CD40L-trimer leads to a homogeneous cell population with enhanced surface marker expression and increased cytokine production [J]. Scand J Immunol, 2001, 53(6):579-587.
26. Grewal IS, Flavell RA. CD40 and CD154 in cell mediated immunity [J]. Annu Rev Immunol, 1998, 16(1):111-135.
27. Messmer D, Kipps TJ. CD154 gene therapy for human B-cell malignancies [J]. Ann NY Acad Sci, 2005, 1062 (1):51-60.
28. Liu A, Guardino A, Chinsangaram L, et al. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand [J]. Cancer Res, 2007, 67(14):7037-7044.
29. Tripp RA, Jones L, Anderson LJ, et al. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse [J]. J Immunol, 2000, 164(11):5913-5921.
30. Manoj S, Griebel PJ, Babiuk LA, et al. Modulation of immune responses to bovine herpesvirus-1 in cattle by immunization with a DNA vaccine encoding glycoprotein D as a fusion protein with bovine CD154 [J]. Immunology, 2004, 112(2):328-338.
31. Chen HW, Huang HI, Lee YP, et al. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment [J]. Cancer Immunol Immunother, 2002, 51(6):341-348.
32. Chen G, Darrah PA, Mosser DM. Vaccination against the intracellular pathogens Leishmania major and L. amazonensis by directing CD40 ligand to macrophages [J]. Infect Immunol, 2001, 69(5):3255-3263.
33. Molling JW, de Gruijl TD, Glim J, et al. CD4 (+) CD25 (hi) regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia [J]. Int J Cancer, 2007, 121(8):1749-1755.
34. Yu P, Lee Y, Liu W, et al. Intratumor depletion of CD4 + cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors [J]. J Exp Med, 2005, 201(5):779-791.